Manage Your Liver
Q:

Prevent liver cell damage: A new era of liver disease treatment

Prevent liver cell damage: A new era of liver disease treatment
A:

There are between 10 to 15 million patients in the U.S. with NASH, and among these patients, one-fifth to one-fourth are at risk for cirrhosis or chronic liver damage.

 

The major characteristic of NASH is fat in the liver, along with inflammation and damage. NASH can be severe and can lead to cirrhosis. The number of NASH cirrhosis patients is currently on the rise, and it is predicted (NAFLD & NASH) to be the number 1 cause of liver transplants by 2020. [1] Therefore, pharmaceutical companies have recently shifted their focus onto the development of cure for fatty liver and NASH.

 

As the cause of NASH is still unknown, to date, there are no available treatment options. Unlike hepatitis C, where the liver damage is caused by hepatitis viruses; the only thing we know about NASH is that the accumulated fat is related to liver injury, but the mechanism is unknown. . In this case, anti-viral medication will not be effective for NASH patients.

 

New drug in development focuses on preventing liver cell damage

New drugs for NASH are in development,  they are designed to block the progression of liver cell damage, prevent chronic liver inflammation and cirrhosis, and ultimately help to improve liver function for NASH patients.

 

Pharmaceutical companies are hoping that this new drug can minimize liver injury and help NASH patients to reduce risk of developing chronic liver diseases. The drug is currently under clinical trial; enrolment of a final-stage trial of 2,000 people is expected to be completed next year, with interim results due in 2019. Early results show that the new drug can lower patients’ ALT level, which is a good indication that liver injury is reduced. [2] 

 

New drugs may improve but not normalize liver function

The use of chemicals and drugs in treating liver diseases has its downsides. Patients are required to use the inhibitor in the long term in order to prevent liver injury this means that they will be consuming chemicals and toxins on a daily basis. Regardless of the intensity of side effects, long term use of any medication will no doubt negatively affect our health.

 

This might be the reason why the new drugs in development are unable to normalize ALT and liver function, even though liver damage may be reduced. These drugs themselves contain toxic substances which are harmful to our bodies in some way.

 

If you want to know more about the upcoming new drugs and how YHK can help to stop NASH, please contact our support team!

Disclaimer:
  • * All research and clinical data should be used as reference purposes only, results may vary.
Tags:
YHK TherapyYHK LiverPrevent liver cell damageNASHNASH Treatment
Related Questions
A:
Research and developing our products has always been a big part of our work. Kyotsujigyo has worked with a number of well established organisations and universities in the past, including the University of Sao Paulo, GAIA Age-Management Foundation, The University of Western Ontario, University of Virginia, Yanaihara Research Institute,  Harada Hospital (Japan) and others.    In 2016 Kyotsujigyo has corporate with the National Key Research Institute in Hong K
A:
NASH is inflammation in the liver developed from accumulated fat in the organ, also known as fatty liver. NASH damages liver cells and liver function, which results in elevated ALT liver enzyme level.    As there are no approved treatments for NASH, the standard recommendation for patients is to lose weight only. However this doesn’t work for everyone so if you are struggling to find a way to stop NASH, please read on.   Wha
Hit Questions
A:
Research and developing our products has always been a big part of our work. Kyotsujigyo has worked with a number of well established organisations and universities in the past, including the University of Sao Paulo, GAIA Age-Management Foundation, The University of Western Ontario, University of Virginia, Yanaihara Research Institute,  Harada Hospital (Japan) and others.    In 2016 Kyotsujigyo has corporate with the National Key Research Institute in Hong K
A:
NASH is inflammation in the liver developed from accumulated fat in the organ, also known as fatty liver. NASH damages liver cells and liver function, which results in elevated ALT liver enzyme level.    As there are no approved treatments for NASH, the standard recommendation for patients is to lose weight only. However this doesn’t work for everyone so if you are struggling to find a way to stop NASH, please read on.   Wha
A:
In 2010, some 4.7 million people aged 65 years or older lived with Alzheimer's disease in the US.   Alzheimer’s is a common brain disease that causes progressive brain cell death that happens over a course of time. It will also cause a shrink in brain size as the tissue has progressively fewer nerve cells and connections. Alzheimer’s is thought to be caused by Protein Plaques building up in the brain cells, these Plaques are found between the dying cel
A:
YHK is a clinically proven liver therapy, research data shows that YHK can effectively lower ALT enzymes level and improve liver function within just 10-30 days without any side effects.   Having said that everyone might experience different levels of improvement, as each persons liver condition is different and YHK is not a type of chemical medicine, each individually will require different amount of YHK. In order to maximise the effects finding the right dosage is t
YHK Liver Therapy
Your Liver
Protection

starts here.
Buy YHK
Have Questions?
Sumbit your question to us for profeessional answers!
Have
Questions?
Sumbit your question
to us for profeessional answers!
YHK Liver Therapy
Your Liver
Protection

starts here.
Buy YHK
Looking for help? Ask our customer support team!
Contact Us